Story thread · 4 reports / 4 sources
Roche Obesity Shot Cuts Body Weight 15.5% in Mid-Stage Trial
bloomberg.com · 7h · first report
How the coverage leans
Across 4 sources · syndicated copies counted once
Roche Holding AG’s experimental obesity shot enicepatide reduced both blood sugar and body weight in patients with type 2 diabetes who were overweight or obese in a mid-stage trial.
The coverage
- Roche obesity drug shows 15.5% weight loss in diabetes trial
investing.com · 1h
- Roche reports Phase 2 enicepatide data in overweight or obese patients with diabetes
endpts.com · 2h
- Roche GLP-1 delivers 16% weight loss in mid-stage trial
seekingalpha.com · 2h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.